Universal influenza vaccine compositions
AssigneeGylden Pharma Limited
InventorRamila Philip
Life of this patent
Estimating the term…
Abstract
The invention provides a vaccine composition comprising an influenza virus peptide comprising a CD8+ T cell epitope and an influenza virus peptide comprising a B cell epitope, wherein each peptide is attached to a nanoparticle.
Claims11
A method of stimulating an immune response in an individual infected with, or at risk of being infected with, an influenza virus, comprising administering an immunogenic composition to the individual, wherein the-immunogenic composition comprises an influenza virus peptide comprising one or more of the CD8+ T cell epitopes set out in SEQ ID NOs:
- 1 to 21, wherein the peptide is attached to a gold glyconanoparticle, and wherein the glyconanoparticle further comprises one or more ligands comprising a carbohydrate moiety selected from the group consisting of:
- glucose, N-Acetylglucosamine (GlcNAc), 2′-thioethyl-β-D-glucopyranoside, and 2′-thioethyl-D-glucopyranoside, wherein the immunogenic composition comprises two or more influenza virus peptides each comprising a different CD8+ T cell epitope.
A method of stimulating an immune response in an individual infected with, or at risk of being infected with, an influenza virus, comprising administering an immunogenic composition to the individual, wherein the-immunogenic composition comprises an influenza virus peptide comprising one or more of the CD8+ T cell epitopes set out in SEQ ID NOs:
- 1 to 21, wherein the peptide is attached to a gold glyconanoparticle, and wherein the glyconanoparticle further comprises one or more ligands comprising a carbohydrate moiety selected from the group consisting of:
- glucose, N-Acetylglucosamine (GlcNAc), 2′-thioethyl-β-D-glucopyranoside, and 2′-thioethyl-D-glucopyranoside, wherein the immunogenic composition further comprises an influenza virus peptide comprising a CD4+ T cell epitope.
A method of stimulating an immune response in an individual infected with, or at risk of being infected with, an influenza virus, comprising administering an immunogenic composition to the individual, wherein the-immunogenic composition comprises an influenza virus peptide comprising one or more of the CD8+ T cell epitopes set out in SEQ ID NOs:
- 1 to 21, wherein the peptide is attached to a gold glyconanoparticle, and wherein the glyconanoparticle further comprises one or more ligands comprising a carbohydrate moiety selected from the group consisting of:
- glucose, N-Acetylglucosamine (GlcNAc). 2′-thioethyl-β-D-glucopyranoside, and 2′-thioethyl-D-glucopyranoside, wherein the influenza virus peptide comprising a CD8+ T cell epitope further comprises a CD4+ T cell epitope.
A method of stimulating an immune response in an individual infected with, or at risk of being infected with, an influenza virus, comprising administering an immunogenic composition to the individual, wherein the-immunogenic composition comprises an influenza virus peptide comprising one or more of the CD8+ T cell epitopes set out in SEQ ID NOs:
- 1 to 21, wherein the peptide is attached to a gold glyconanoparticle, and wherein the glyconanoparticle further comprises one or more ligands comprising a carbohydrate moiety selected from the group consisting of:
- glucose, N-Acetylglucosamine (GlcNAc), 2′-thioethyl-β-D-glucopyranoside, and 2′-thioethyl-D-glucopyranoside, wherein the immunogenic composition comprises at least two influenza virus peptides comprising a CD8+ T cell epitope which each interacts with a different HLA supertype.
A method of stimulating an immune response in an individual infected with, or at risk of being infected with, an influenza virus, comprising administering an immunogenic composition to the individual, wherein the-immunogenic composition comprises an influenza virus peptide comprising one or more of the CD8+ T cell epitopes set out in SEQ ID NOs:
- 1 to 21, wherein the peptide is attached to a gold glyconanoparticle, and wherein the glyconanoparticle further comprises one or more ligands comprising a carbohydrate moiety selected from the group consisting of:
- glucose, N-Acetylglucosamine (GlcNAc), 2′-thioethyl-β-D-glucopyranoside, and 2′-thioethyl-D-glucopyranoside, wherein the immunogenic composition comprises at least one immunogenic peptide that interacts with at least two different HLA supertypes.
Dependencies are inferred from the claim text.